Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus

被引:135
作者
Ward, MM
Pyun, E
Studenski, S
机构
[1] STANFORD UNIV,SCH MED,DIV RHEUMATOL & IMMUNOL,STANFORD,CA 94305
[2] DUKE UNIV,MED CTR,DIV RHEUMATOL & IMMUNOL,DURHAM,NC
[3] UNIV KANSAS,MED CTR,CTR AGING,KANSAS CITY,KS 66103
关键词
D O I
10.1001/archinte.156.12.1337
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Mortality in patients with systemic lupus erythematosus (SLE) is often related to disease in particular organ systems. We examined the risks of mortality associated with 8 clinical manifestations of SLE and determined whether these risks differed among patients with different sociodemographic characteristics. Methods: Using life table analysis, we determined the associations of hemolytic anemia, leukopenia, thrombocytopenia, arthritis, serositis, nephritis, psychosis, and seizures with both all-cause mortality and SLE-related mortality in a cohort of 408 patients. Results: Over a median duration of follow-up of 11 years, 144 patients died; 78 deaths (54%) were SLE related. In univariate analyses, the presence of hemolytic anemia, serositis, nephritis, psychosis, and seizures was associated with greater all-cause mortality, while the presence of arthritis was protective. In multivariate analyses that controlled for patient demographic characteristics, nephritis (relative risk, 2.34) and seizures (relative risk, 1.77) were associated with poorer overall survival. Nephritis and seizures, along with thrombocytopenia, were also associated with greater SLE-related mortality, while leukopenia was protective. The risk of death in association with these clinical manifestations did not differ among patient age, sex, race, or socioeconomic subgroups. Conclusions: The presence of nephritis and seizures each increased the risk of death in patients with SIE approximately 2-fold. Thrombocytopenia also increased the risk of SLE-related mortality, while leukopenia was protective.
引用
收藏
页码:1337 / 1344
页数:8
相关论文
共 37 条
  • [1] CLINICAL-FEATURES OF SYSTEMIC LUPUS-ERYTHEMATOSUS - DIFFERENCES RELATED TO RACE AND AGE OF ONSET
    BALLOU, SP
    KHAN, MA
    KUSHNER, I
    [J]. ARTHRITIS AND RHEUMATISM, 1982, 25 (01): : 55 - 60
  • [2] THE ACTUAL SURVIVAL RATE IN SYSTEMIC LUPUS-ERYTHEMATOSUS - STUDY OF A 1976 COHORT
    BREBAN, M
    MEYER, O
    BOURGEOIS, P
    PALAZZO, E
    KAHN, MF
    [J]. CLINICAL RHEUMATOLOGY, 1991, 10 (03) : 283 - 288
  • [3] HEMATOLOGIC ASPECTS OF SYSTEMIC LUPUS-ERYTHEMATOSUS - CURRENT CONCEPTS
    BUDMAN, DR
    STEINBERG, AD
    [J]. ANNALS OF INTERNAL MEDICINE, 1977, 86 (02) : 220 - 229
  • [4] COX DR, 1972, J R STAT SOC B, V34, P187
  • [5] DRENKARD C, 1994, J RHEUMATOL, V21, P1067
  • [6] DUBOIS EL, 1964, JAMA-J AM MED ASSOC, V190, P104
  • [7] MAJOR HISTOCOMPATIBILITY COMPLEX GENES AND SUSCEPTIBILITY TO SYSTEMIC LUPUS-ERYTHEMATOSUS
    FRONEK, Z
    TIMMERMAN, LA
    ALPER, CA
    HAHN, BH
    KALUNIAN, K
    PETERLIN, BM
    MCDEVITT, HO
    [J]. ARTHRITIS AND RHEUMATISM, 1990, 33 (10): : 1542 - 1553
  • [8] A MULTI-CENTER STUDY OF OUTCOME IN SYSTEMIC LUPUS-ERYTHEMATOSUS .1. ENTRY VARIABLES AS PREDICTORS OF PROGNOSIS
    GINZLER, EM
    DIAMOND, HS
    WEINER, M
    SCHLESINGER, M
    FRIES, JF
    WASNER, C
    MEDSGER, TA
    ZIEGLER, G
    KLIPPEL, JH
    HADLER, NM
    ALBERT, DA
    HESS, EV
    SPENCERGREEN, G
    GRAYZEL, A
    WORTH, D
    HAHN, BH
    BARNETT, EV
    [J]. ARTHRITIS AND RHEUMATISM, 1982, 25 (06): : 601 - 611
  • [9] OUTCOME OF SYSTEMIC LUPUS-ERYTHEMATOSUS - A STUDY OF 66 PATIENTS OVER 7 YEARS WITH SPECIAL REFERENCE TO THE PREDICTIVE VALUE OF ANTI-DNA ANTIBODY DETERMINATIONS
    GRIPENBERG, M
    HELVE, T
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1991, 20 (02) : 104 - 109
  • [10] GUDMUNDSSON S, 1990, J RHEUMATOL, V17, P1162